Thromboembolism and Bleeding in COVID-19

Koray Durak
Additional contact information
Koray Durak: Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands

J, 2021, vol. 4, issue 3, 1-10

Abstract: Coronavirus disease 2019 (COVID-19) is characterized by a coagulation dysfunction which has different underlying mechanisms and factors. Patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection have an increased risk for thromboembolic and bleeding complications. Incidences are high, and mainly consist of venous thromboembolism (VTE), which significantly contributes to morbidity and mortality in affected patients. Thromboprophylaxis is recommended in all hospitalized COVID-19 patients. Therapeutic doses of antithrombotic agents are only beneficial in noncritically ill patients, and usual care thromboprophylaxis is sufficient in critically ill patients at the ICU. Regarding screening for VTE, high quality evidence is warranted to investigate the significance of asymptomatic DVT in the ICU setting and its influence on PE and mortality.

Keywords: COVID-19; thromboembolism; thrombosis; thromboprophylaxis; bleeding; ECLS (search for similar items in EconPapers)
JEL-codes: I1 I10 I12 I13 I14 I18 I19 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2571-8800/4/3/36/pdf (application/pdf)
https://www.mdpi.com/2571-8800/4/3/36/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jjopen:v:4:y:2021:i:3:p:36-485:d:622469

Access Statistics for this article

J is currently edited by Ms. Angelia Su

More articles in J from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().